Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells

Karin Anestål, Stefanie Prast-Nielsen, Narimantas Cenas et al. · 2008

Read Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells by Karin Anestål, Stefanie Prast-Nielsen, Narimantas Cenas et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001846.txt.

Introduction

Karin Anestål and co-authors studied how an antioxidant enzyme can be turned into a cell killer in a 2008 PLOS ONE research article. SecTRAPs are selenium-compromised thioredoxin reductase-derived apoptotic proteins. They form from the selenoprotein thioredoxin reductase when its selenocysteine residue is targeted by electrophiles, or when the protein's tail is cut off.

Once converted, these proteins act as prooxidants that kill cells rather than protect them. The full text gives the conversion conditions and the cell death assays. A protective enzyme flipped into a killer is a possible cancer drug principle: tumor cells, rich in this enzyme, would arm the weapon themselves.

Catalog record

CREATORKarin Anestål, Stefanie Prast-Nielsen, Narimantas Cenas et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001846

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells Authors: Karin Anestål, Stefanie Prast-Nielsen, Narimantas Cenas, Elias S. J. Arnér Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001846 ABSTRACT SecTRAPs ( se lenium c ompromised t hioredoxin r eductase-derived a poptotic p rotein s) can be formed from the selenoprotein thioredoxin reductase (TrxR) by targeting of its selenocysteine (Sec) residue with electrophiles, or by its removal through C-terminal truncation. SecTRAPs are devoid of thioredoxin reductase activity but can induce rapid cell death in cultured cancer cell lines by a gain of function. Both human and rat SecTRAPs killed human A549 and HeLa cells. The cell death displayed both apoptotic and necrotic features. It did not require novel protein synthesis nor did it show extensive nuclear fragmentation, but it was attenuated by use of caspase inhibitors. The redox active disulfide/dithiol motif in the N-terminal domain of TrxR had to be maintained for manifestation of SecTRAP cytotoxicity. Stopped-flow kinetics showed that NADPH can reduce the FAD moiety in SecTRAPs at similar rates as in native TrxR and purified SecTRAPs could maintain NADPH oxidase activity, which was accelerated by low molecular weight substrates such as juglone. In a cellular context, SecTRAPs triggered extensive formation of reactive oxygen species (ROS) and consequently antioxidants could protect against the cell killing by SecTRAPs. We conclude that formation of SecTRAPs could contribute to the cytotoxicity seen upon exposure of cells to electrophilic agents targeting TrxR. SecTRAPs are prooxidant killers of cells, triggering mechanisms beyond those of a mere loss of thioredoxin reductase activity. INTRODUCTION Mammalian thioredoxin reductases (TrxR, E.C. 1.8.1.9.) are selenoproteins, i.e. they belong to the unique family of proteins that contain a selenocysteine (Sec, U in one-letter code) residue [1] – [3] . TrxR has, together with the principal substrate thioredoxin (Trx), a wide range of functions in cells as a major reducing system for DNA synthesis, redox regulatory functions and antioxidant defense [4] – [9] . Three mammalian isoenzymes of TrxR have been identified, namely the most abundant predominantly cytosolic TrxR1 [1] , [3] , mitochondrial TrxR2 [10] – [12] and TGR (thioredoxin glutathione reductase), the latter mainly expressed in testis [13] , [14] . It should be noted, in the context of this study, that TrxR proteins of other organisms such as bacteria, archaea, plants or insects, are typically not selenoproteins. There is also a lack of consensus for nomenclature of TrxR, sometimes abbreviated as TR or TXNRD, with additional abbreviations occurring, e.g. mitochondrial TrxR2 is the same enzyme as TR3 and TGR has also been called TR2. Mammalian TrxR1 is a homodimeric protein with the two subunits arranged head to tail [15] . The first phases of the catalytic cycle involve a transfer of electrons from NADPH via an enzyme-bound FAD to a disulfide in the CVNVGC motif located in the N-terminal domain, which is highly homologous to the mechanisms of glutathione reductase and other members of the enzyme family [15] – [19] . The electrons in TrxR1 are subsequently transferred from the dithiol of the reduced CVNVGC motif to a selenenylsulfide within the C-terminal -GCUG motif of the other subunit in the dimeric holoenzyme. The selenenylsulfide is thereby reduced to a selenolthiol, which can finally reduce the disulfide in the active site of Trx or other substrates of TrxR [15] , [17] , [18] , [20] . Alternative substrates for TrxR in addition to Trx encompass additional protein disulfide substrates [21] , [22] as well as several low molecular weight compounds, such as selenite [23] , lipoic acid [24] , ascorbate [25] or quinones [26] , [27] . Sec is a selenium-containing analog to cysteine but a stronger nucleophile with a low p K a , which makes Sec a highly reactive amino acid [28] . The reactivity of Sec is essential for the native catalytic activity of mammalian TrxR [18] , [20] . However, the presence of Sec in TrxR at an easily accessible C-terminal position renders the enzyme highly susceptible to irreversible inhibition by derivatization of the Sec residue. Thus, TrxR can be inhibited by a wide range of electrophilic compounds, many of them used in anti-inflammatory or anticancer treatment. Such compounds include auranofin [29] , arsenic trioxide [30] , several alkylating quinones [27] , platinum-containing anticancer drugs [31] – [34] , and additional classical alkylating anticancer agents including nitrosourea [34] , [35] , melphalan and chlorambucil [34] . Endogenously produced electrophilic prostaglandin derivatives can also target the enzyme [36] . It is easily conceivable that an inhibitor of TrxR would impose a significant stress on cells due to the resulting inhibition of thioredoxin-dependent reactions, the outcome of which would depend upon the state and growth condition of the target cell [5] , [6] , [9] . In addition, we previously found that derivatization of the Sec residue in TrxR1 with electrophilic compounds may infer a gain of function to the protein as a potent and direct inducer of cell death [37] . A truncated form of TrxR1 lacking the two last amino acids (–Sec-Gly) also induced cell death when introduced into cells, while the full-length enzyme with normal enzymatic activity did not [37] . Cytotoxic effects previously described for TrxR1 in the form of GRIM-12 [38] – [42] seem to have been due to combinations of TrxR1-dependent p53 activation and apoptosis induced by Sec-deficient forms of TrxR1, as earlier discussed in detail [37] . The mechanism of the cell death triggered by cytotoxic forms of selenium compromised TrxR1-derived proteins has hitherto been unknown. In order to distinguish the unique properties of these proteins from those of native TrxR1 enzyme, we have named them SecTRAPs for se lenium c ompromised t hioredoxin r eductase-derived a poptotic p rotein s, thereby referring to derivatives of mammalian TrxR that have i, a compromised Sec residue, ii, no Trx reducing capability and iii, the capacity to induce cell death by a gain of function. The term SecTRAP also refers to the “trap” for electrophilic compounds that the Sec residue in TrxR constitutes due to its high nucleophilicity. In the present study, we have analyzed the means by which SecTRAPs induce cell death. We show here that not all forms of TrxR1 with a compromised Sec residue show cytotoxic properties as SecTRAPs. Only forms of the modified protein having an intact N-terminal CVNVGC motif and being able to propagate NADPH oxidase activity could induce cell death. This cell death had both apoptotic and necrotic features and it correlated to an increased intracellular oxidative stress. The findings suggest that the antioxidant selenoprotein TrxR1 under some circumstances can be converted into a potent prooxidant killer of cells. MATERIALS AND METHODS The BioPORTER Quick easy protein delivery reagent was obtained from Gene therapy systems. Fetal calf serum (FCS) came from Biotech Line AS, whereas Dulbeccos modified Eagle medium, L-glutamine, phosphate buffered saline (PBS) and PCR-primers were from Invitrogen. Antibiotics were purchased from BIO-Whittaker Belgium. Ascorbic acid (Vit C), bovine serum albumin (BSA), Cycloheximide, 2′-(4-Ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5′-bi-1H-benzimidazole (Hoechst 33342), juglone, propidium iodide (PI), tumor necrosis factor-α (TNF-α), α-tocopherol (Vit E), 2′,7′-dichlorofluorescein (DCFH) and staurosporine (STS) came from Sigma-Aldrich Chemical Co. Cisplatin (Platinol®, cis-diamminedichloroplatinum; CDDP) came from Bristol Myers Squibb. zVAD-fmk was obtained from Promega, zDEVD-fmk from Biosource and

Read the complete text